Proximagen company

Proximagen is a publicly traded neuroscience research company focused on drug development for neurodegenerative disorders, including Parkinson's disease and Alzheimer's disease.

Investors

Technology: P4 Medicine
Industry: Personalized Medicine
Headquarters: London, England, United Kingdom
Founded Date: 2003
Employees Number: 11-50
Funding Status: N/A
Investors Number: 1
Total Funding: $96.5M
Estimated Revenue: $1M to $10M
Last Funding Type: Venture - Series Unknown

Visit Website
info@proximagen.com
Register and Claim Ownership